Healthcare Industry News: HSMN NewsFeed
News Release - October 14, 2010
BSD Launches MicroThermX Microwave Ablation System at CIRSE - Europe’s Largest Forum for Interventional Radiology ProductsSALT LAKE CITY--(Healthcare Sales & Marketing Network)-- BSD Medical Corporation (NASDAQ:BSDM ) (the “Company” or “BSD”) announced today that the MicroThermX Microwave Ablation System was featured at the Company’s exhibition booth at the international meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), which was held in Valencia, Spain, October 2-6, 2010. CIRSE is Europe's largest and most comprehensive meeting for minimally invasive interventional radiology/oncology products. Over 5,000 clinicians from 70 different countries around the world attended CIRSE, reflecting the global impact of the rapidly expanding field of interventional radiology. The global market for ablation treatments is expected to reach $2.0 billion.
“The CIRSE meeting was effectively used to increase the profile of the Company’s line of microwave ablation products and to further develop the Company’s association with international key opinion leaders, many of whom frequented BSD’s booth,” stated Steven Smith, VP for Marketing and Business Development for BSD. “The tremendous success of the MicroThermX exhibit was evident by a constant stream of interested clinicians and medical distributors from around the world. BSD was pleased to have numerous medical distributors express excitement about the opportunity of selling the MicroThermX Microwave Ablation System. BSD met with distributors covering all of Latin and North America, Europe, the Mid East, South Africa, and Asia, including China, Korea and Japan.”
The CIRSE scientific program highlighted the growing field of interventional oncology, including a series of presentations on the advantages and developments in the use of thermal ablation techniques in the treatment of solid tumors. One of the presentations reviewed the clinical advantages of microwave ablation, as compared to radiofrequency ablation, as a minimally invasive treatment for malignant solid tumors. The presenters reported that clinicians are embracing the advantages offered by minimally-invasive interventional oncology procedures like microwave ablation, including shorter patient recovery times, greater patient comfort and faster patient throughput.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue and has received marketing clearance from the US FDA. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.